Following a definitive Purchase Agreement, BioNTech has announced its intention to acquire all of the shares of fellow German company CureVac.  With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialisation of investigational mRNA-based cancer immunotherapies.  The company’s oncology strategy focuses on two pan-tumour programmes, mRNA-based cancer immunotherapy candidates, and BNT327, a […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!